| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | 681640 | GDSC1000 | pan-cancer | AAC | 0.0034 | 0.9 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | 0.0069 | 0.9 |
| mRNA | BRD-K30748066 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.9 |
| mRNA | BRD-K92856060 | CTRPv2 | pan-cancer | AAC | -0.0032 | 0.9 |
| mRNA | niclosamide | CTRPv2 | pan-cancer | AAC | -0.0032 | 0.9 |
| mRNA | BRD8899 | CTRPv2 | pan-cancer | AAC | 0.0033 | 0.9 |
| mRNA | JW-55 | CTRPv2 | pan-cancer | AAC | -0.006 | 0.9 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0025 | 0.9 |
| mRNA | SR8278 | CTRPv2 | pan-cancer | AAC | -0.0085 | 0.9 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | -0.0033 | 0.9 |